ARTICLE | Finance

From Phase4 to Mereo

How risk-sharing newco Mereo evolved from Phase4, debuted with Novartis programs

August 3, 2015 7:00 AM UTC

The leadership team behind Phase4 Ventures is branching out from its traditional venture roots to launch newco Mereo BioPharma Group Ltd., which aims to provide an alternative for pharmas looking to advance mid-stage pipelines in the face of resource constraints.

Mereo debuted last week with $119 million (£76.5 million) to develop an initial slate of three programs acquired from Novartis AG, which has an equity stake in the newco. ...